ZIOP insider filings

ZIOPHARM ONCOLOGY INC — 27 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2021-12-27. Screen ZIOP transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for ZIOP between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — ZIOPHARM ONCOLOGY INC

FiledFormInsiderReported transactionsSource
2021-12-274De Groot Eleanor — EVP, OperationsSale (S): 20,132 @ $1.27EDGAR
2021-12-134Lackey Melinda — Senior Vice President, LegalGrant/award (A): 370,000 (derivative) @ $0EDGAR
2021-11-174Boyle Kevin S. Sr. — Chief Executive Officer, DirectorPurchase (P): 884 @ $1.40 · Purchase (P): 9,116 @ $1.40EDGAR
2021-10-044Vieser Jaime — DirectorPurchase (P): 100,000 @ $1.91EDGAR
2021-09-034Hagen Heidi — DirectorPurchase (P): 23,770 @ $1.76EDGAR
2021-09-034Weis Holger — DirectorPurchase (P): 50,000 @ $1.83EDGAR
2021-09-034Postma Robert W — DirectorPurchase (P): 20,508 @ $1.73 · Purchase (P): 54,492 @ $1.73EDGAR
2021-09-034Huang James — DirectorPurchase (P): 100,000 @ $1.71EDGAR
2021-08-314Boyle Kevin S. Sr. — Chief Executive Officer, DirectorGrant/award (A): 875,000 @ $0 · Grant/award (A): 2,625,000 (derivative) @ $0EDGAR
2021-05-194Baffa Raffaele — Chief Medical OfficerGrant/award (A): 80,645 @ $0EDGAR
2021-05-064Weis Holger — DirectorGrant/award (A): 4,167 @ $0 · Grant/award (A): 31,250 (derivative) @ $0 · Grant/award (A): 150,000 (derivative) @ $0EDGAR
2021-05-064Vieser Jaime — DirectorGrant/award (A): 4,167 @ $0 · Grant/award (A): 31,250 (derivative) @ $0 · Grant/award (A): 150,000 (derivative) @ $0EDGAR
2021-05-064Thistle Mary — DirectorGrant/award (A): 5,000 @ $0 · Grant/award (A): 37,500 (derivative) @ $0 · Grant/award (A): 150,000 (derivative) @ $0EDGAR
2021-05-064Postma Robert W — DirectorGrant/award (A): 2,500 @ $0 · Grant/award (A): 18,750 (derivative) @ $0 · Grant/award (A): 150,000 (derivative) @ $0EDGAR
2021-05-064Huang James — DirectorGrant/award (A): 8,333 @ $0 · Grant/award (A): 62,500 (derivative) @ $0EDGAR
2021-05-064BUCHI J KEVIN — DirectorGrant/award (A): 4,167 @ $0 · Grant/award (A): 31,250 (derivative) @ $0EDGAR
2021-05-064Bowden Christopher — DirectorGrant/award (A): 4,167 @ $0 · Grant/award (A): 31,250 (derivative) @ $0EDGAR
2021-03-084Buck Jill — EVP, GM Gene TherapyGrant/award (A): 31,500 @ $0 · Grant/award (A): 236,250 (derivative) @ $0EDGAR
2021-03-084Hadfield Robert — Chief Legal Officer and Sec.Grant/award (A): 43,500 @ $0 · Grant/award (A): 326,250 (derivative) @ $0EDGAR
2021-03-084Hagen Heidi — Interim CEO, DirectorGrant/award (A): 90,000 @ $0 · Grant/award (A): 675,000 (derivative) @ $0EDGAR
2021-03-084De Groot Eleanor — EVP, GM Cell TherapyGrant/award (A): 50,825 @ $0 · Grant/award (A): 381,188 (derivative) @ $0EDGAR
2021-01-124Buck Jill — EVP, GM Gene TherapySale (S): 27,894 @ $3.12EDGAR
2021-01-124Lafond Kevin G — SVP, Treasurer & CAOSale (S): 18,020 @ $3.09EDGAR
2021-01-124Hadfield Robert — General Counsel and SecretarySale (S): 26,500 @ $3.12EDGAR
2021-01-064De Groot Eleanor — EVP, GM Cell TherapySale (S): 21,620 @ $2.72EDGAR
2021-01-064Cooper Laurence James Neil — President and CEO, DirectorSale (S): 105,693 @ $2.71EDGAR
2020-10-134BUCHI J KEVIN — DirectorGrant/award (A): 146,190 (derivative) @ $0EDGAR

Recent 8-K events — ZIOPHARM ONCOLOGY INC

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2026-10-238-K8.01 — Other EventsEDGAR
2026-10-218-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
9.01 — Financial Statements and Exhibits
EDGAR
2026-10-138-K1.01 — Entry into a Material Definitive Agreement
2.01 — Completion of Acquisition or Disposition of Assets
3.02 — Unregistered Sales of Equity Securities
5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
7.01 — Regulation FD Disclosure
9.01 — Financial Statements and Exhibits
EDGAR
2026-10-098-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingEDGAR
2026-09-228-K1.01 — Entry into a Material Definitive Agreement
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-09-178-K3.03 — Material Modification to Rights of Security Holders
5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
EDGAR
2026-06-298-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-05-268-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-05-188-K8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-04-158-K3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingEDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=ZIOP returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs